Fennec Pharmaceuticals, Inc. (FENC)
12.76
+1.14
(+9.81%)
USD |
NASDAQ |
Nov 16, 16:00
12.58
-0.18
(-1.41%)
After-Hours: 20:00
Fennec Pharmaceuticals Net Income (Quarterly) : 4.64M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 4.64M |
| June 30, 2026 | 1.973M |
| March 31, 2026 | 0.201M |
| December 31, 2025 | -5.144M |
| September 30, 2025 | -0.638M |
| June 30, 2025 | -3.152M |
| March 31, 2025 | -1.165M |
| December 31, 2024 | -1.619M |
| September 30, 2024 | -5.735M |
| June 30, 2024 | -5.553M |
| March 31, 2024 | 12.84M |
| December 31, 2023 | -2.682M |
| September 30, 2023 | -1.867M |
| June 30, 2023 | -5.444M |
| March 31, 2023 | -6.052M |
| December 31, 2022 | -6.857M |
| September 30, 2022 | -8.089M |
| June 30, 2022 | -5.072M |
| March 31, 2022 | -3.696M |
| December 31, 2021 | -4.427M |
| September 30, 2021 | -4.185M |
| June 30, 2021 | -4.001M |
| March 31, 2021 | -4.733M |
| December 31, 2020 | -3.238M |
| September 30, 2020 | -6.20M |
| Date | Value |
|---|---|
| June 30, 2020 | -4.845M |
| March 31, 2020 | -3.826M |
| December 31, 2019 | -3.61M |
| September 30, 2019 | -1.809M |
| June 30, 2019 | -4.73M |
| March 31, 2019 | -2.626M |
| December 31, 2018 | -2.984M |
| September 30, 2018 | -2.749M |
| June 30, 2018 | -2.587M |
| March 31, 2018 | -1.568M |
| December 31, 2017 | -2.29M |
| September 30, 2017 | -2.352M |
| June 30, 2017 | -1.598M |
| March 31, 2017 | -0.806M |
| December 31, 2016 | -1.143M |
| September 30, 2016 | -0.502M |
| June 30, 2016 | -0.724M |
| March 31, 2016 | -0.42M |
| December 31, 2015 | -0.54M |
| September 30, 2015 | -0.123M |
| June 30, 2015 | -0.173M |
| March 31, 2015 | 0.177M |
| December 31, 2014 | 1.388M |
| September 30, 2014 | 0.38M |
| June 30, 2014 | -0.75M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -42.99M |
| Arrowhead Pharmaceuticals, Inc. | -428.88M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 19.61M |
| Total Expenses (Quarterly) | 14.97M |
| EPS Diluted (Quarterly) | 0.1219 |
| Enterprise Value | 400.66M |
| Gross Profit Margin (Quarterly) | 95.73% |
| Profit Margin (Quarterly) | 23.66% |
| Earnings Yield | 0.13% |
| Operating Earnings Yield | 0.72% |
| Normalized Earnings Yield | 0.4867 |